JP2019524672A - 聴覚疾患の処置のための内耳への薬物化合物の送達の薬物動態、治療効果、および安全性の定量的評価のための方法およびプロセス - Google Patents

聴覚疾患の処置のための内耳への薬物化合物の送達の薬物動態、治療効果、および安全性の定量的評価のための方法およびプロセス Download PDF

Info

Publication number
JP2019524672A
JP2019524672A JP2018567745A JP2018567745A JP2019524672A JP 2019524672 A JP2019524672 A JP 2019524672A JP 2018567745 A JP2018567745 A JP 2018567745A JP 2018567745 A JP2018567745 A JP 2018567745A JP 2019524672 A JP2019524672 A JP 2019524672A
Authority
JP
Japan
Prior art keywords
pack composition
peg
thiol
mol
ester
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018567745A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019524672A5 (https=
Inventor
ジェフリー ティー． ボレンスタイン
ジェフリー ティー． ボレンスタイン
エリン パララス
エリン パララス
アーネスト エス． キム
アーネスト エス． キム
ヴィシャル タンドン
ヴィシャル タンドン
アンドリュー アヨオブ
アンドリュー アヨオブ
マイケル マケナ
マイケル マケナ
ウィリアム シューエル
ウィリアム シューエル
マルチェッロ ペッピ
マルチェッロ ペッピ
マーク ワインバーグ
マーク ワインバーグ
ロバート ランガー
ロバート ランガー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Charles Stark Draper Laboratory Inc
Original Assignee
Charles Stark Draper Laboratory Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Charles Stark Draper Laboratory Inc filed Critical Charles Stark Draper Laboratory Inc
Publication of JP2019524672A publication Critical patent/JP2019524672A/ja
Publication of JP2019524672A5 publication Critical patent/JP2019524672A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0046—Ear
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2018567745A 2016-06-23 2017-06-23 聴覚疾患の処置のための内耳への薬物化合物の送達の薬物動態、治療効果、および安全性の定量的評価のための方法およびプロセス Pending JP2019524672A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662353676P 2016-06-23 2016-06-23
US62/353,676 2016-06-23
PCT/US2017/039090 WO2017223498A1 (en) 2016-06-23 2017-06-23 Method and process for quantitative evaluation of pharmacokinetics, therapeutic effects and safety of delivery of drug compounds to the inner ear for treatment of auditory diseases

Publications (2)

Publication Number Publication Date
JP2019524672A true JP2019524672A (ja) 2019-09-05
JP2019524672A5 JP2019524672A5 (https=) 2020-07-30

Family

ID=59297388

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018567745A Pending JP2019524672A (ja) 2016-06-23 2017-06-23 聴覚疾患の処置のための内耳への薬物化合物の送達の薬物動態、治療効果、および安全性の定量的評価のための方法およびプロセス

Country Status (5)

Country Link
US (1) US10596267B2 (https=)
EP (1) EP3474852A1 (https=)
JP (1) JP2019524672A (https=)
AU (1) AU2017281928B2 (https=)
WO (1) WO2017223498A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023524824A (ja) * 2020-05-06 2023-06-13 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｋｅｌｃｈドメイン含有７Ｂ（ＫＬＨＤＣ７Ｂ）バリアント及びその使用

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020254249A1 (en) 2019-06-21 2020-12-24 Proqr Therapeutics Ii B.V. Delivery of nucleic acids for the treatment of auditory disorders

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100015263A1 (en) * 2008-07-21 2010-01-21 Otonomy, Inc. Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders
US20130085476A1 (en) * 2011-09-26 2013-04-04 InClube Labs, LLC System and method for delivery of a therapeutic agent to the inner ear
US20140200395A1 (en) * 2012-12-11 2014-07-17 Bilal Shafi Apparatuses and methods for preventing or reversing heart dilation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8099156B1 (en) * 2006-09-15 2012-01-17 The Board Of Trustees Of The Leland Stanford Junior University Cochlear optical analysis system and approach therefor
US8883185B2 (en) * 2010-05-27 2014-11-11 Covidien Lp Hydrogel implants with varying degrees of crosslinking

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100015263A1 (en) * 2008-07-21 2010-01-21 Otonomy, Inc. Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders
US20130085476A1 (en) * 2011-09-26 2013-04-04 InClube Labs, LLC System and method for delivery of a therapeutic agent to the inner ear
US20140200395A1 (en) * 2012-12-11 2014-07-17 Bilal Shafi Apparatuses and methods for preventing or reversing heart dilation

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
INTERNATIONAL JOURNAL OF PHARMACEUTICS, vol. 470, JPN6020025392, 2014, pages 151 - 157, ISSN: 0004305239 *
INTERNATIONAL JOURNAL OF PHARMACEUTICS, vol. 503, JPN6020025394, 2016, pages 229 - 237, ISSN: 0004305240 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023524824A (ja) * 2020-05-06 2023-06-13 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｋｅｌｃｈドメイン含有７Ｂ（ＫＬＨＤＣ７Ｂ）バリアント及びその使用

Also Published As

Publication number Publication date
EP3474852A1 (en) 2019-05-01
US20180000956A1 (en) 2018-01-04
WO2017223498A1 (en) 2017-12-28
US10596267B2 (en) 2020-03-24
AU2017281928A1 (en) 2019-02-07
AU2017281928B2 (en) 2023-04-13
CA3029319A1 (en) 2017-12-28

Similar Documents

Publication Publication Date Title
Hao et al. Inner ear drug delivery: recent advances, challenges, and perspective
Thakur et al. Microneedle-mediated intrascleral delivery of in situ forming thermoresponsive implants for sustained ocular drug delivery
Bao et al. Exosome-loaded degradable polymeric microcapsules for the treatment of vitreoretinal diseases
Roy et al. Microneedle ocular patch: Fabrication, characterization, and ex-vivo evaluation using pilocarpine as model drug
Salt et al. Local inner-ear drug delivery and pharmacokinetics
Liu et al. Current strategies for drug delivery to the inner ear
Salt et al. Principles of local drug delivery to the inner ear
Thakur et al. Rapidly dissolving polymeric microneedles for minimally invasive intraocular drug delivery
Ayoob et al. The role of intracochlear drug delivery devices in the management of inner ear disease
Patel et al. Suprachoroidal drug delivery to the back of the eye using hollow microneedles
Chiang et al. Distribution of particles, small molecules and polymeric formulation excipients in the suprachoroidal space after microneedle injection
Wang et al. Dose-dependent sustained release of dexamethasone in inner ear cochlear fluids using a novel local delivery approach
Salt et al. Perilymph pharmacokinetics of locally-applied gentamicin in the guinea pig
Zhao et al. A hydrogel ionic circuit based high‐intensity iontophoresis device for intraocular macromolecule and nanoparticle delivery
Kelso et al. Microperforations significantly enhance diffusion across round window membrane
Chen et al. Dexamethasone-loaded injectable silk-polyethylene glycol hydrogel alleviates cisplatin-induced ototoxicity
Staecker et al. Developments in delivery of medications for inner ear disease
Honeder et al. Sustained release of triamcinolone acetonide from an intratympanically applied hydrogel designed for the delivery of high glucocorticoid doses
Yu et al. Complete restoration of hearing loss and cochlear synaptopathy via minimally invasive, single-dose, and controllable middle ear delivery of brain-derived neurotrophic Factor–Poly (dl-lactic acid-co-glycolic acid)-loaded hydrogel
Creber et al. Adjuvant agents enhance round window membrane permeability to dexamethasone and modulate basal to apical cochlear gradients
Wang et al. Effects of PEO− PPO− PEO triblock copolymers on phospholipid membrane integrity under osmotic stress
Santimetaneedol et al. Small molecule delivery across a perforated artificial membrane by thermoreversible hydrogel poloxamer 407
Qing et al. Ropivacaine-loaded hydrogels for prolonged relief of chemotherapy-induced peripheral neuropathic pain and potentiated chemotherapy
Bruk et al. Controlled release of ciprofloxacin and ceftriaxone from a single ototopical administration of antibiotic-loaded polymer microspheres and thermoresponsive gel
JP2019524672A (ja) 聴覚疾患の処置のための内耳への薬物化合物の送達の薬物動態、治療効果、および安全性の定量的評価のための方法およびプロセス

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200619

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200619

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20200619

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20200706

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200715

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210301